HIV integrase inhibitors: cyclic pyrimidinone compounds

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S211120, C514S267000, C514S230200, C544S230000, C544S070000, C544S071000, C540S542000, C540S543000

Reexamination Certificate

active

11273671

ABSTRACT:
The invention encompasses a series of pyrimidinone compounds which inhibit HIV integrase and thereby prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses intermediates useful for making the pyrimidone compounds. Additionally, pharmaceutical compositions and methods for treating those infected with HIV are encompassed.

REFERENCES:
patent: 2004/0006065 (2004-01-01), Giunz
patent: WO 03/035076 (2003-05-01), None
patent: WO 03/035077 (2003-05-01), None
patent: WO 2004/058756 (2004-07-01), None
patent: WO 2004/058757 (2004-07-01), None
patent: WO 2005/061490 (2005-07-01), None
patent: WO 2005/061501 (2005-07-01), None
patent: WO 2005/070901 (2005-08-01), None
U.S. Appl. No. 10/755,642, filed Jan. 12, 2004, Michael A. Walker et al.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

HIV integrase inhibitors: cyclic pyrimidinone compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with HIV integrase inhibitors: cyclic pyrimidinone compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV integrase inhibitors: cyclic pyrimidinone compounds will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3905808

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.